IDYA

$34.27

Market ClosedAs of Mar 17, 8:00 PM UTC

IDEAYA Biosciences, Inc., a precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States.

OverviewIntradayAnalysisPROIntelligencePROAsk AIPRO

Historical Price

Price (Line)
Synthesizing Whystock Narrative...
Loading Financials...

Peer Comparison

JNJUNHPFE

Whystock Valuation Model

Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$34.27
Potential Upside
5%
Whystock Fair Value$35.98
Price
UndervaluedFair ValueOvervalued

Fundamentals

SectorHealthcare
IndustryBiotechnology

IDEAYA Biosciences, Inc., a precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company offers Darovasertib, an oral, potent, and sel...

Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$3.01B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.03
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Average efficiency. Growth may require heavy reinvestment.
-10.92%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
10.97

Recent News

Zacks
Mar 9, 2026

DAWN Stock Jumps 66% on $2.5B Buyout Offer From Servier

Day One's stock surges 66% after Servier agrees to acquire it for $21.50 per share in a $2.5B deal, adding brain tumor drug Ojemda and oncology pipeline assets.

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Insider Monkey
Mar 6, 2026

IDEAYA Biosciences, Inc. (IDYA) Enrolls First Patient in Phase 1 Trial of IDE034 Bispecific ADC

IDEAYA Biosciences, Inc. (NASDAQ:IDYA) is among the 10 Fastest Growing NASDAQ Stocks to Buy. On February 25, 2026, IDEAYA Biosciences, Inc. (NASDAQ:IDYA) announced that the first patient has been enrolled in its Phase 1 dose escalation and expansion trial evaluating IDE034, an investigational PTK7/B7H3 bispecific TOP1 ADC. The company plans to evaluate the safety, tolerability, […]

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
Simply Wall St.
Feb 28, 2026

Assessing IDEAYA Biosciences (IDYA) Valuation After IDE034 First-In-Human Dosing Milestone

IDEAYA Biosciences (IDYA) is in focus after dosing the first patient with IDE034 in a Phase 1 trial, a key step for this bispecific TOP1 antibody drug conjugate and its partnership with Biocytogen. See our latest analysis for IDEAYA Biosciences. IDEAYA's recent IDE034 dosing news sits alongside a run of company updates, including a new Chief Development Officer, a shelf registration filing and full year 2025 results. The latest share price of $32.20 comes after a 1 year total shareholder...

BULLISH
Positive press. Headlines skewed toward growth and analyst upgrades.
MarketBeat
Feb 23, 2026

IDEAYA Biosciences Teases Late-March Phase III Darovasertib Readout, ADC Updates, New KAT6/7 Phase I Launch

IDEAYA Biosciences (NASDAQ:IDYA) outlined upcoming clinical milestones for its precision oncology pipeline, emphasizing an imminent top-line readout in first-line metastatic uveal melanoma (MUM), continued advancement of its antibody-drug conjugate (ADC) portfolio, and the early clinical launch of a

BEARISH
Negative press. News cycle fixated on risk factors or misses.
MarketBeat
Feb 23, 2026

IDEAYA Biosciences Teases End-of-March Data for Darovasertib Combo at Citi Oncology Summit

IDEAYA Biosciences (NASDAQ:IDYA) executives outlined multiple upcoming clinical catalysts at Citi’s 2026 Virtual Oncology Leadership Summit, led by an end-of-March top-line readout for the company’s randomized trial of darovasertib plus crizotinib in metastatic uveal melanoma (MUM). Management also

BEARISH
Negative press. News cycle fixated on risk factors or misses.